Major General James G. Blunt

Batanopride (BMY-25,801) is an antiemetic drug of the benzamide class which acts as a selective 5-HT3 receptor antagonist.[1] It was trialled to reduce nausea during cancer chemotherapy, but was never approved for medical use due to dose-limiting side effects including hypotension and long QT syndrome.[2]

References

  1. ^ Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR (March 1988). "BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties". The Journal of Pharmacology and Experimental Therapeutics. 244 (3): 830–7. PMID 2978041.
  2. ^ Fleming GF, Vokes EE, McEvilly JM, Janisch L, Francher D, Smaldone L (1991). "Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis". Cancer Chemotherapy and Pharmacology. 28 (3): 226–7. doi:10.1007/bf00685516. PMID 1855280. S2CID 22520773.
source: https://en.wikipedia.org/wiki/Batanopride